blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3922637

EP3922637 - MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  12.11.2021
Database last updated on 11.09.2024
Most recent event   Tooltip16.02.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2021/50]
Inventor(s)01 / EBNETH, Andreas
2300 Turnhout / BE
02 / VAN OUTRYVE D'YDEWALLE, Constantin
3020 Herent / BE
03 / GRYAZNOV, Sergei
San Mateo, CA 94402 / US
04 / MARTÍNEZ MONTERO, Saúl
San Bruno, CA 94066 / US
 [2021/50]
Representative(s)Snaith, James Michael
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[N/P]
Former [2021/50]Quaghebeur, Luc
Johnson & Johnson
Patent Law Department
Turnhoutseweg 30
2340 Beerse / BE
Application number, filing date21170299.813.03.2019
[2021/50]
Priority number, dateUS201862642499P13.03.2018         Original published format: US 201862642499 P
[2021/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3922637
Date:15.12.2021
Language:EN
[2021/50]
Search report(s)(Supplementary) European search report - dispatched on:EP11.11.2021
ClassificationIPC:C07H21/00, C12N15/113, A61K31/7088, A61P25/28
[2021/50]
CPC:
C07H21/00 (EP,IL,KR); C12N15/113 (EP,IL,KR,US); A61K31/7125 (EP,IL,KR);
A61P25/28 (EP,IL,KR,US); C12N2310/11 (EP,IL,KR,US); C12N2310/315 (EP,IL,KR,US);
C12N2310/321 (EP,IL,KR,US); C12N2310/322 (EP,IL,KR); C12N2310/3341 (US);
C12N2310/335 (EP,IL,KR); C12N2310/341 (EP,IL,KR); C12N2310/345 (EP,IL,KR);
C12N2310/346 (US); C12N2310/3521 (IL); C12N2310/3525 (IL);
C12N2320/50 (US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP);
C12N2310/322, C12N2310/3525 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/50]
Extension statesBA23.04.2021
ME23.04.2021
Validation statesKH23.04.2021
MA23.04.2021
MD23.04.2021
TN23.04.2021
TitleGerman:MODIFIZIERTE OLIGONUKLEOTIDE ZUR VERWENDUNG BEI DER BEHANDLUNG VON TAUOPATHIEN[2021/50]
English:MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES[2021/50]
French:OLIGONUCLÉOTIDES MODIFIÉS POUR UNE UTILISATION DANS LE TRAITEMENT DE TAUOPATHIES[2021/50]
Examination procedure23.04.2021Examination requested  [2021/50]
08.07.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.09.2022Amendment by applicant (claims and/or description)
Parent application(s)   TooltipEP19712535.4  / EP3765476
Request for further processing for:The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
12.09.2022Request for further processing filed
12.09.2022Full payment received (date of receipt of payment)
Request granted
22.09.2022Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
12.09.2022Request for further processing filed
12.09.2022Full payment received (date of receipt of payment)
Request granted
22.09.2022Decision despatched
Fees paidRenewal fee
23.04.2021Renewal fee patent year 03
17.02.2022Renewal fee patent year 04
14.02.2023Renewal fee patent year 05
15.02.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YD]WO0118015  (GERON CORP [US], et al) [YD] 1-33 * abstract * * page 3, line 16 - page 5, line 14 *;
 [Y]US2014121261  (GRYAZNOV SERGEI M [US], et al) [Y] 1-33 * abstract * * [0106]-[0108] *;
 [XY]WO2015010135  (ISIS PHARMACEUTICALS INC [US]) [X] 1,2,4-7,11-17,19-22,26-33 * the whole document * * SEQ ID NO: 124; pages 57, 70 * * SEQ ID NO: 1768; page 109 * * SEQ ID NO: 2136; page 119 * * tables 9-66 * * pages 22-26; compounds Ia, IIa, IIIa, IVa, Va * * page 35, lines 5-20 * [Y] 3,8-10,18,23-25;
 [Y]WO2016126995  (BRISTOL MYERS SQUIBB CO [US], et al) [Y] 1-33 * abstract * * [0166], [0246]-[0251], [0314]-[0347] * * figures 2, 3, 6, 7, 16 and 20 *;
 [Y]WO2017109679  (NOVARTIS AG [CH]) [Y] 1-33 * abstract * * [0005]-[0011], [0027], [0030]-[0031], [0036], [0065]-[0078], [0083] *;
 [Y]  - KRISZTINA PONGRACZ ET AL, "Novel Short Oligonucleotide Conjugates as Inhibitors of Human Telomerase", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS., US, (20031001), vol. 22, no. 5-8, doi:10.1081/NCN-120023085, ISSN 1525-7770, pages 1627 - 1629, XP055434021 [Y] 1-33 * the whole document *

DOI:   http://dx.doi.org/10.1081/NCN-120023085
 [Y]  - LOUIS P. CONWAY ET AL, "The synthesis, conformation and hydrolytic stability of an N,S-bridging thiophosphoramidate analogue of thymidylyl-3',5'-thymidine", ORGANIC & BIOMOLECULAR CHEMISTRY, (20160101), vol. 14, no. 30, doi:10.1039/C6OB01270A, ISSN 1477-0520, pages 7361 - 7367, XP055606690 [Y] 1-33 * the whole document * * compound 1 *

DOI:   http://dx.doi.org/10.1039/C6OB01270A
 [Y]  - R. SCHULTZ ET AL, "Oligo-2'-fluoro-2'-deoxynucleotide N3'-->P5' phosphoramidates: synthesis and properties", NUCLEIC ACIDS RESEARCH, (19960801), vol. 24, no. 15, doi:10.1093/nar/24.15.2966, pages 2966 - 2973, XP055626548 [Y] 1-33 * the whole document *

DOI:   http://dx.doi.org/10.1093/nar/24.15.2966
by applicantUS6268490
 US6525191
 US6770748
 US6794499
 US7034133
 US7053207
 US7084125
 US7217805
 US7314923
 US7569575
 US7696345
    - DEVOS et al., "miRNA mimics or inhibitors, aptamers, steric blockers, saRNA, shRNA, and/or immunomodulatory oligonucleotides", Sci Transl Med, (20170125), vol. 9, no. 374
    - HANGER et al., Trends Mol Med, (20090000), vol. 15, pages 112 - 9
    - WISCHIK et al., Proc Natl Acad Sci USA., (19880000), vol. 85, pages 4884 - 8
    - MORRIS et al., Neuron, (20110000), vol. 70, pages 410 - 26
    - Nucleic Acids Research, (19950000), vol. 23, no. 14, pages 2661 - 2668
    - Nucleic Acids Research, (19960000), vol. 24, no. 15, pages 2966 - 2973
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.